The state of Florida currently has 130 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Recruiting
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/06/2025
Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Recruiting
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
05/06/2025
Locations: University of Miami School of Medicine, Miami, Florida
Conditions: Hodgkin Lymphoma
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
Recruiting
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
05/06/2025
Locations: Research Site, Miami, Florida
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Recruiting
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Richter's Syndrome (RS): * epcoritamab + lenal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida +1 locations
Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/05/2025
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida +2 locations
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Recruiting
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Boca Raton Clinical Research (BRCR) Global, Plantation, Florida
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL)
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Recruiting
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/05/2025
Locations: Florida Cancer Specialists - South, Fort Myers, Florida +8 locations
Conditions: Large B-cell Lymphoma
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Recruiting
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Florida Cancer Specialists - South, Fort Myers, Florida +4 locations
Conditions: Lymphoma, Follicular
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Recruiting
The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University of Miami, Miami, Florida
Conditions: CNS Lymphoma
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Recruiting
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Large B-cell Lymphoma
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Recruiting
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2025
Locations: UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida +9 locations
Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2025
Locations: Holy Cross Hospital, Fort Lauderdale, Florida +1 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma